Who Paid My Doc
Humphrey Atiemo
Urogynecology and Reconstructive Pelvic Surgery Toledo, OH Medical Doctor
NPI 1245293299 CMS profile 55865
2120 W Central Ave, Toledo, OH 43606
General payments
$3,343
Research payments
$2,096
Ownership & investment interest
$0
Research they led as principal investigator
$14,204
Through program year 2025, Humphrey Atiemo of Toledo, OH is reported in the CMS Open Payments database as having received $3,343 across 67 general payments and $2,096 in research payments paid to them. Separately, studies naming them as principal investigator received $14,204 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 42nd percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $586 | 28 | |
| 2024 | General | $209 | 11 | |
| 2023 | General | $319 | 6 | |
| 2022 | General | $1,592 | 12 | |
| 2022 | Research | $2,096 | 1 | |
| 2021 | General | $165 | 4 | |
| 2020 | General | $367 | 4 | |
| 2019 | General | $106 | 2 |
Beside peers
- Humphrey Atiemo
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Humphrey Atiemo were reported at $586. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.
Show as a table
| Year | Humphrey Atiemo | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $106 | $799 | $319–$2,013 | $163 |
| 2020 | $367 | $384 | $158–$1,360 | $114 |
| 2021 | $165 | $641 | $247–$2,515 | $132 |
| 2022 | $1,592 | $843 | $347–$2,794 | $149 |
| 2023 | $319 | $819 | $308–$2,302 | $160 |
| 2024 | $209 | $882 | $306–$2,459 | $164 |
| 2025 | $586 | $779 | $301–$2,705 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
713
Drug cost
$103,828
Branded share of claims
25.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 107 | $57,728 | |
| Estradiol | Generic | 205 | $12,690 | |
| Mirabegron Er Mirabegron | Brand | 20 | $9,935 | |
| Gemtesa Vibegron | Brand | 20 | $9,712 | |
| Methenamine Hippurate | Generic | 92 | $7,734 | |
| Solifenacin Succinate | Generic | 66 | $3,060 | |
| Trospium Chloride | Generic | 41 | $2,089 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 32 | $300 | |
| Desmopressin Acetate | Generic | 11 | $142 | |
| Ciprofloxacin Hcl | Generic | 62 | $137 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 58 billing codesPaid by Medicare
$89,139
Medicare patients
277
Services billed
7,193
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 68% | |
| Diabetes | 42% | |
| Chronic kidney disease | 40% | |
| Heart failure | 32% | |
| Ischemic heart disease | 31% | |
| Depression | 31% | |
| Atrial fibrillation | 26% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 15 | 102 | $14,338 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 11 | 192 | $146 |
| Injection, garamycin, gentamicin, up to 80 mg J1580 | Office | 11 | 16 | $31 |
| Injection, heparin sodium, per 1000 units J1644 | Office | 11 | 160 | $29 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
4 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| XYOSTED |
|
$46 | — | — |
| BOTOX |
|
$34 | — | — |
| GEMTESA |
|
$22 | 20 | — |
| JELMYTO |
|
$17 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
68 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Ohio
Mickey Karram
Urogynecology and Reconstructive Pelvic Surgery · West Chester, OH
Emily Slopnick
Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OH
Ly Hoang Roberts
Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OH
Omer Anis
Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OH
Nadine Kassis
Urogynecology and Reconstructive Pelvic Surgery · Toledo, OH
Chen Shenhar
Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OH
Related records
Urogynecology and Reconstructive Pelvic Surgery in Ohio
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Ohio
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.